- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
BrightInsight, Inc, the trusted partner and platform driving value for top biopharma compliant digital health solutions, announced today that it will deplo...
Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...
Thermo Fisher Scientific, the world leader in serving science, was proud to welcome Jozef Sikela, Minister of Industry and Trade of the Czech Republic, alo...
BrioHealth Solutions, Inc., a medical technology company focused on developing innovative advanced heart failure solutions, announced it has received FDA I...
The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. NKGen Biotech, Inc. , a clinical-stage biotechnology company focused on the dev...
Celltrion USA announced that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on b...
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corpor...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombo...
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), adv...
The quest for efficiency without compromising safety and compliance is paramount. This was the central theme of the panel discussion titled "Reimag...
Industry pioneers Maria Batalha, Kevin J. Bittorf, Matthew Mollan, and John Nadzam took center stage at INTERPHEX 2024 to share their expertise and insight...
© 2025 Biopharma Boardroom. All Rights Reserved.
